International Journal of Clinical Oncology

, Volume 20, Issue 2, pp 332–337 | Cite as

Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients

  • Yoichiro YoshidaEmail author
  • Seiichiro Hoshino
  • Naoya Aisu
  • Masayasu Naito
  • Syu Tanimura
  • Ai Mogi
  • Toshihiro Tanaka
  • Keiji Hirata
  • Kazuo Tamura
  • Yuichi Yamashita
Original Article



Repeated venous punctures are usually required during chemotherapy administration for cancer patients. Central venous catheters and implantable port systems have substantially facilitated vascular access, and safe, easy-to-handle port systems have become an integral part of daily clinical routines in oncology. However, several serious complications are associated with central venous ports (CV-ports), and recent developments of combined oral capecitabine and oxaliplatin (XELOX) therapies allow CV-port-free administration. In this study, the safety and efficacy of CV-port-free chemotherapy administration via the median cubital vein was assessed in metastatic colorectal cancer patients.


This study included 144 patients who received XELOX + bevacizumab (BV) or XELOX therapy for metastatic colorectal cancer without CV-port implantation.


Eighty-five patients experienced transient vascular pain. The drip infusion route was switched to the opposite side following vascular pain in only 1 patient. No patients required CV-port implantation or delayed treatment due to adverse events associated with drug administration via the peripheral vein. Grade 3 or higher hemotoxicity and grade 3 or higher non-hematological toxicity was noted in 12.5 and 17.4 % of patients, respectively.


Port-free-chemotherapy administration via the median cubital vein is appropriate for patients with colorectal cancer, thereby avoiding complications associated with CV-ports.


Chemotherapy Colorectal cancer Central venous port Median cubital vein 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Niederhuber JE, Ensminger W, Gyves JW et al (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92:706–712PubMedGoogle Scholar
  2. 2.
    Torramadé JR, Cienfuegos JA, Hernández JL et al (1993) The complications of central venous access systems: a study of 218 patients. Eur J Surg 159:323–327PubMedGoogle Scholar
  3. 3.
    Mansfield PF, Hohn DC, Fornage BD et al (1994) Complications and failures of subclavian-vein catheterization. N Engl J Med 331:1735–1738PubMedCrossRefGoogle Scholar
  4. 4.
    Teichgräber UK, Gebauer B, Benter T et al (2004) Long-term central venous lines and their complications. Rofo 176:944–992 (in German)PubMedCrossRefGoogle Scholar
  5. 5.
    Kuwahara T, Asanami S, Kubo S (1998) Experimental infusion phlebitis: tolerance osmolality of peripheral venous endothelial cells. Nutrition 14:496–501PubMedCrossRefGoogle Scholar
  6. 6.
    Nakayama S, Matsubara N, Sakai T et al (2002) The incidence of phlebitis in the patients administrated vinorelbine by intravenous bolus injection—a retrospective study. Gan To Kagaku Ryoho 29:633–635 (in Japanese)PubMedGoogle Scholar
  7. 7.
    Curran CF, Luce JK, Page JA (1990) Doxorubicin-associated flare reactions. Oncol Nurs Forum 17:387–389PubMedGoogle Scholar
  8. 8.
    Matsuyama K, Mishima H, Ueno H et al (2011) Etiology and management of venous pain during intravenous administration of oxaliplatin. Gan To Kagaku Ryoho 38:411–414PubMedGoogle Scholar
  9. 9.
    Yoshida Y, Hoshino S, Aisu N et al (2012) Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. Br J Med Med Res 2:132–141CrossRefGoogle Scholar
  10. 10.
    Petrioli R, Pascucci A, Francini E et al (2008) Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 61:105–111PubMedCrossRefGoogle Scholar
  11. 11.
    Kiernan MC, Krishnan AV (2006) The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 13:2901–2907PubMedCrossRefGoogle Scholar
  12. 12.
    Jordan K, Behlendorf T, Surov A et al (2008) Venous access ports: frequency and management of complications in oncology patients. Onkologie 31(404–410):14Google Scholar
  13. 13.
    Fonkalsrud EW, Pederson BM, Murphy J et al (1968) Reduction of infusion thrombophlebitis with buffered glucose solutions. Surgery 63:280–284Google Scholar
  14. 14.
    Saif MW, Katirtzoglou NA, Syrigos KN (2008) Capecitabine: an overview of the side effects and their management. Anticancer Drugs 19:447–464PubMedGoogle Scholar
  15. 15.
    Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012PubMedCrossRefGoogle Scholar
  16. 16.
    Tsunoda A, Yasuda N, Nakao K et al (2009) Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 77:192–196PubMedCrossRefGoogle Scholar
  17. 17.
    Ishida H, Miyake Y, Fukunaga M et al (2009) A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. Jpn J Clin Oncol 39:601–605PubMedCrossRefGoogle Scholar
  18. 18.
    Eastridge BJ, Lefor AT (1995) Complications of indwelling venous access devices in cancer patients. J Clin Oncol 13:233–238PubMedGoogle Scholar
  19. 19.
    de Gregorio MA, Miguelena JM, Fernández JA et al (1996) Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients. Eur Radiol 6:748–752PubMedCrossRefGoogle Scholar
  20. 20.
    Schwarz R, Groeger J, Coit D (1997) Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer 79:1635–1640PubMedCrossRefGoogle Scholar
  21. 21.
    Kock HJ, Pietsch M, Krause U et al (1998) Implantable vascular access systems: experience in 1,500 patients with totally implanted central venous port systems. World J Surg 22:12–16PubMedCrossRefGoogle Scholar
  22. 22.
    Biffi R, de Braud F, Orsi F et al (1998) Totally implantable central venous access ports for long-term chemotherapy: a prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol 9:767–773PubMedCrossRefGoogle Scholar
  23. 23.
    Lorch H, Zwaan M, Kagel C et al (2001) Central venous access ports placed by interventional radiologists: experience with 125 consecutive patients. Cardiovasc Intervent Radiol 24:180–184PubMedCrossRefGoogle Scholar
  24. 24.
    Vardy J, Engelhardt K, Cox K et al (2004) Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature. Br J Cancer 91:1045–1049PubMedCentralPubMedGoogle Scholar
  25. 25.
    Inaba Y, Yamaura H, Sato Y et al (2007) Central venous access port-related complications in outpatient chemotherapy for colorectal cancer. Jpn J Clin Oncol 37:951–954PubMedCrossRefGoogle Scholar
  26. 26.
    Kameyama H, Yamazaki T, Maeda C et al (2010) Central venous access port devices (CVAPD)-related complications in colorectal cancer patients. Gan To Kagaku Ryoho 37:453–455 (in Japanese)PubMedGoogle Scholar
  27. 27.
    Silberzweig JE, Sacks D, Khorsandi AS, Society of Interventional Radiology Technology Assessment Committee et al (2000) Reporting standards for central venous access. J Vasc Interv Radiol 11:391–400PubMedCrossRefGoogle Scholar
  28. 28.
    Yukisawa S, Fujiwara Y, Yamamoto Y et al (2010) Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol 83:850–853PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Nobili E, Di Cicilia R, Di Battista M et al (2010) Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. Pathophysiol Haemost Thromb 37:30–34PubMedCrossRefGoogle Scholar
  30. 30.
    Walshe LJ, Malak SF, Eagan J et al (2002) Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 20:3276–3281PubMedCrossRefGoogle Scholar
  31. 31.
    Yoshida Y, Hoshino S, Shiwaku H et al (2011) Early start of chemotherapy after resection of primary colon cancer with synchronous multiple liver metastases: a case report. Case Rep Oncol 4:250–254PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Yoshida Y (2012) Port free chemotherapy for recurrent or metastatic colorectal cancer. Is port really necessary? J Cancer Sci Ther 4:iv–iv. doi: 10.4172/1948-5956.1000e105
  33. 33.
    Yoshida Y, Hoshino S, Miyake T et al (2012) Early start of chemotherapy after resection of brain metastasis from colon cancer with synchronous multiple liver metastases. Case Rep Oncol 5:290–295PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Yoshida Y, Hoshino S, Miyake T et al (2013) Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01). World J Surg Oncol 7(11):39CrossRefGoogle Scholar
  35. 35.
    Yoshida Y, Hoshino S, Aisu N et al (2014) Efficacy of XELOX plus bevacizumab in brain metastasis from rectal cancer. Case Rep Oncol 7:117–121PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Eremin O, Marshall V (1977) Complications of intravenous therapy: reduction by buffering of intravenous fluid preparation. Med J Aust 2:528–531PubMedGoogle Scholar
  37. 37.
    Driscoll DF, Newton DW, Bistrian BR (1994) Precipitation of calcium phosphate from parenteral nutrient fluids. Am J Hosp Pharm 51:2834–2836PubMedGoogle Scholar
  38. 38.
    Hill SE, Heldman LS, Goo ED et al (1996) Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. J Parenter Enteral Nutr 20:81–87CrossRefGoogle Scholar
  39. 39.
    Kuwahara T, Asanami S, Kawauchi Y et al (1999) Experimental infusion phlebitis: tolerance pH of peripheral vein. J Toxicol Sci 24:113–121PubMedCrossRefGoogle Scholar
  40. 40.
    Jerremalm E, Eksborg S, Ehrsson H (2003) Hydrolysis of oxaliplatin-evaluation of the acid dissociation constant for the oxalato monodentate complex. J Pharm Sci 92:436–438PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2014

Authors and Affiliations

  • Yoichiro Yoshida
    • 1
    Email author
  • Seiichiro Hoshino
    • 1
  • Naoya Aisu
    • 1
  • Masayasu Naito
    • 1
  • Syu Tanimura
    • 1
  • Ai Mogi
    • 2
  • Toshihiro Tanaka
    • 2
  • Keiji Hirata
    • 3
  • Kazuo Tamura
    • 2
  • Yuichi Yamashita
    • 1
  1. 1.Department of Gastroenterological SurgeryFukuoka University Faculty of MedicineFukuokaJapan
  2. 2.Division of Oncology, Hematology and Infectious Diseases, Department of Internal MedicineFukuoka University Faculty of MedicineFukuokaJapan
  3. 3.Department of SurgeryFukuoka Sanno HospitalFukuokaJapan

Personalised recommendations